Recently, programmed necrosis is found in cancer cell death by anticancer agents.29, 32 Activation of the canonical programmed necrosis includes the formation of a complex containing RIP3 and RIP1 (RIPK1) and recruitment of mixed lineage kinase domain‐like protein (MLKL).33, 34. This evidence concerns the gene RIPK3 and cancer.